Atypical Hyperplasia of the BreastNCT04496739
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
A study testing Cancer Educational Materials, Decision Aid and Interview in people with Atypical Hyperplasia of the Breast and Lobular Breast Carcinoma In Situ, run by SWOG Cancer Research Network at 97 sites in 2 countries.
Trial summary
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are designed to improve informed choice about breast cancer chemoprevention. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- What is being tested?
- Cancer Educational Materials, Decision Aid and Interview
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 412 participants
- Where
- 97 sitesin 2 countries
- Study dates
- 23 Oct 2020to 1 Jun 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Patients must have histologically-confirmed atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) documented by breast pathology report at any time in the past. Patients with borderline breast lesions and pleomorphic LCIS are also eligible
- Patients must be women at least 35 and no more than 74 years of age at registration, since the Breast Cancer Surveillance Consortium (BCSC) risk calculator is valid only for this age range
- Both pre/perimenopausal and postmenopausal women are eligible
- Patients must be able to read and write in English or Spanish since study questionnaires and educational materials are only available in English and Spanish
- Baseline questionnaires must be completed prior to patient registration
- The S1904 Patient Contact form must be completed prior to patient registration
Show all 22Show fewer
- Patients must be able to access the internet and receive email or text messages. This is required to access study materials and receive email/text message reminders from the S1904 Study Team at Columbia University Irving Medical Center (CUIMC). The patient decision aid, RealRisks, is accessible via smartphones, tablets, or personal computers. If patients do not own these devices, local study personnel will provide resources for patients to access RealRisks via computer kiosks or tablets in clinic waiting rooms or public locations, such as community centers or public libraries
- Patients and healthcare providers must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- IMPLEMENTATION: Providers who enrolled in S1904 at Group 2 (intervention) recruitment center and consented to future contact are eligible to participate in the interviews
- IMPLEMENTATION EVALUATION: Patients who registered to S1904 at a Group 2 (Intervention) Recruitment Center and consented to be contacted for future research are eligible to participate in the interviews
- Recruitment Centers must be National Clinical Trials Network (NCTN), National Cancer Institute Community Oncology Research Program (NCORP) or Minority Underserved (MU)-NCORP institutions
- Recruitment Centers must have an active EHR and patient portal used in the outpatient clinics which is common and accessible across all sites belonging to the Recruitment Center
- Recruitment Centers must be willing to allow the S1904 study team access to the site's application program interface (API) for integration of the study materials (standard educational materials and decision support tools) into the EHR and patient portal. (NOTE: Both Group 1 (control) and Group 2 (intervention) recruitment centers may access the standard educational materials via the patient portal or uniform resource locator (URL)/website)
- Recruitment centers must see at least 50 AH and/or LCIS patients per year
- Recruitment centers must identify a lead principal investigator (PI) to facilitate recruitment and retention of patients and healthcare providers and to participate in quarterly stakeholder meetings/conference calls
- Recruitment centers must be willing to register at about 16 patients and 5 healthcare providers to the study
- Recruitment Centers must be willing to submit monthly screening logs to CUIMC
- Providers must regularly see patients with AH or LCIS at an approved recruitment center
- Providers must be willing to provide informed consent and complete an online baseline questionnaire
- Providers who will register patients must be registered members of a Cooperative Group
- Providers who register patients to S1904 must be willing to see those same patients for their 6-month study visits, as the provider intervention tools require that the "treating investigator" as designated in OPEN and the provider at the 6-month study visit be the same
Who cannot join
- Patients must not have a history of invasive breast cancer or ductal carcinoma in situ
- Patients must not have prior or current use of selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs)
- NOTE: The following are approved SERMS and AIs, however, the study is not limited to these.
- SERMs: tamoxifen, raloxifene
- AIs: anastrozole, exemestane, letrozole
- Patients must not be currently taking hormone replacement therapy
Show all 9Show fewer
- Patients must not have a history of bilateral mastectomies or breast implants since the risk calculator is not applicable to these women
- Patients must not be pregnant or lactating
- Premenopausal patients must not have a history of thromboembolism, since it is a contraindication to tamoxifen. Tamoxifen is the only Food and Drug Administration (FDA)-approved drug for breast cancer chemoprevention among high-risk premenopausal women, whereas postmenopausal women are eligible for both SERMs and AIs
Trial locations and contacts
97 sites in 2 countries.
97 sites in 2 countries
United States96 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Queen's Cancer Center - Pearlridge
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
The Queen's Medical Center - West Oahu
‘Ewa Beach, Hawaii, 96706
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Grady Health System
Atlanta, Georgia, 30303
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180
IU Health West Hospital
Avon, Indiana, 46123
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Beverly Hospital
Beverly, Massachusetts, 01915
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Loyola Center for Health at Burr Ridge
Burr Ridge, Illinois, 60527
IU Health North Hospital
Carmel, Indiana, 46032
Centralia Oncology Clinic
Centralia, Illinois, 62801
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee, 38017
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Memorial Sloan Kettering Commack
Commack, New York, 11725
Good Samaritan Hospital
Corvallis, Oregon, 97330
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, 92627
Carle at The Riverfront
Danville, Illinois, 61832
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Memorial Sloan Kettering Westchester
East White Plains, New York, 10604
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, 54701
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii, 96817
Hawaii Diagnostic Radiology Services LLC
Honolulu, Hawaii, 96817
Kuakini Medical Center
Honolulu, Hawaii, 96817
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, 46202
Straub Medical Center - Kahului Clinic
Kahului, Hawaii, 96732
Castle Medical Center
Kailua, Hawaii, 96734
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Loyola University Medical Center
Maywood, Illinois, 60153
Holy Redeemer Hospital and Medical Center
Meadowbrook, Pennsylvania, 19046
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Baptist Memorial Hospital for Women
Memphis, Tennessee, 38120
Miami Cancer Institute
Miami, Florida, 33176
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Peninsula Cancer Institute-Newport News
Newport News, Virginia, 23601
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Kaiser Permanente-Oakland
Oakland, California, 94611
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068
Miami Cancer Institute at Plantation
Plantation, Florida, 33324
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Virginia Cancer Institute
Richmond, Virginia, 23229
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Kaiser Permanente Downtown Commons
Sacramento, California, 95814
Kaiser Permanente-South Sacramento
Sacramento, California, 95823
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Kaiser San Rafael-Gallinas
San Rafael, California, 94903
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California, 95051
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
VCU Community Memorial Health Center
South Hill, Virginia, 23970
City of Hope South Pasadena
South Pasadena, California, 91030
Kaiser Permanente-South San Francisco
South San Francisco, California, 94080
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin, 54241
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
Carle Cancer Center
Urbana, Illinois, 61801
The Carle Foundation Hospital
Urbana, Illinois, 61801
Kaiser Permanente-Vallejo
Vallejo, California, 94589
Kaiser Permanente-Walnut Creek
Walnut Creek, California, 94596
Aurora West Allis Medical Center
West Allis, Wisconsin, 53227
Winchester Hospital
Winchester, Massachusetts, 01890
Shenandoah Oncology PC
Winchester, Virginia, 22601
About this study
Official title: Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are designed to improve informed choice about breast cancer chemoprevention. Recognizing barriers and facilitators that can influence the adoption of decision support tools at recruitment centers may help researchers learn how to best implement them into clinical practice.
Read the detailed description
PRIMARY OBJECTIVE:
- To compare the frequency of chemoprevention informed choice at 6 months after registration among women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) between the intervention (RealRisks decision aid/breast cancer risk navigation [BNAV] + standard educational materials) and control (standard educational materials alone) arms.
SECONDARY OBJECTIVES:
- To assess patient chemoprevention knowledge, chemoprevention intention/decision, perceived breast cancer risk and worry, accuracy of breast cancer risk perception, decision conflict and decision regret at baseline, 6 months, and 12 months in the intervention and control arms.
II. To compare patient chemoprevention usage, adherence, and reasons for discontinuation of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) annually for up to 5 years between the intervention and control arms.
III. To assess shared decision-making about chemoprevention among patients and healthcare providers after their 6-month clinic visit in the intervention and control arms.
IMPLEMENTATION OBJECTIVE:
- To assess the implementation of the decision support tools, RealRisks and BNAV, into clinic workflow, and to better understand barriers and facilitators to chemoprevention usage by conducting telephone/video-conference interviews of healthcare providers and high-risk women with AH or LCIS assigned to the active intervention.
OUTLINE: Recruitment centers are randomized to 1 of 2 groups.
GROUP I (CONTROL): Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
GROUP II (INTERVENTION): Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the electronic health record (EHR). A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
After completion of study, patients are followed up at 6, 12, 24, 36, 48, and 60 months.
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Being tested
- Cancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
- Medical subject headings
- Breast Carcinoma In Situ
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cancer Educational MaterialsBehavioural
Receive educational materials about breast cancer risk and chemoprevention via RealRisk
Decision AidOther
Given patient-centered decision support via an action plan
Decision AidOther
Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool
InterviewOther
Participate in audio-recorded interview via telephone or video conference
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Group I (educational materials) | Active comparator | Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Receives: Behavioral: Cancer Educational Materials; Other: Questionnaire Administration |
| Group II (educational materials, decision support, interview) | Experimental | Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual. Receives: Behavioral: Cancer Educational Materials; Other: Decision Aid; Other: Interview; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Chemoprevention informed choice
Will be provided by chemoprevention knowledge scale, a 1-item attitudes scale, and chemoprevention decision and measure at 6 and 12 months on the S1904 Follow-Up Choice form. All enrolled patients who provide outcomes data at the 6-month timepoint will be included in the primary analysis under the intention-to-treat principle. The primary analysis of the intervention effect on informed choice at 6 months will be based on a logistic regression model using a generalized estimating equation approach to account for clustering. Additional supportive analyses will adjust for both patient and clinic level factors. If there are substantial missing data for the components of the primary endpoint, a sensitivity analysis will be conducted imputing a response of no informed decision making for those women with missing information.
Measured: At 6 months
Secondary outcomes (10)
Perceived breast cancer risk
Will be assessed by absolute estimate ("How do you rate your chance of developing breast cancer?"), comparative risk ("Overall, how do you think your chance of developing breast cancer compares to the average woman your age?"), and numeric risk ("Please place an X on the line below at the point showing what you think your chance is of developing breast cancer in the next five years"). All are assessed on a scale of 0% to 100%, with 0% as "no chance of breast cancer" and 100% as "definitely will get breast cancer."
Measured: Up to 12 months
Actual breast cancer risk score
A numeric score between the values of 0% and 100%, as determined by the Breast Cancer Surveillance Consortium (BCSC) risk models. The 5-year and 10-year risk estimates are used. The items needed for the BCSC risk models are obtained at baseline from the S1904 Onstudy.
Measured: Up to 12 months
Accuracy of risk perception
Will be defined as the difference between numeric perceived breast cancer 10-year risk estimate (subjective) and actual 10-year breast cancer risk score, according to the BCSC risk model (objective). Categorized as: accurate if the difference between subjective and objective risk estimates are =< 10% in either direction; underestimate if > 10% below objective risk; and overestimate if > 10% above objective risk.
Measured: Up to 12 months
Breast cancer worry
Will be measured by two Likert-style items, with responses ranging from "Not at all" (1) to "All of the time" (7). Items are reported and scored separately. Breast cancer worry is assessed on the S1904 Breast Cancer Risk Questionnaire.
Measured: Up to 12 months
Decision conflict
Will be assessed on the S1904 Breast Cancer Risk Questionnaire. Will be measured by a validated 10-item scale with 3 response categories (Yes/Unsure/No) to assess the level of conflict women feel about their decisions regarding chemoprevention. Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict) and will be scored according to the User Manual - Decisional Conflict Scale.
Measured: Up to 12 months
Decision regret
Will be assessed on the S1904 Decision Questionnaire. Will be measured by a validated 5-item scale composed of 5-point Likert-style items. Scores that range from 0 (no regret) to 100 (high regret). It is scored according to the User Manual - Decision Regret Scale.
Measured: Up to 12 months
Chemoprevention usage
Will be assessed on the S1904 Follow-Up form and the S1904 Breast Cancer Risk-Reducing Pill Usage form. Among patients who do not have a diagnosis of invasive breast cancer or ductal carcinoma in situ, it will be defined as reporting having started taking or currently taking a selective estrogen receptor modulators (SERM) or aromatase inhibitor (AI) for primary prevention, as assessed by self-report, and taking at least one dose of a SERM or AI for primary prevention, as assessed by the site based on the electronic health record log. Both measures will be reported. Reasons for never starting chemoprevention will be recorded.
Measured: Up to 5 years
Chemoprevention adherence
Will be assessed using a 3-item scale for patients currently taking a SERM or AI. Responses are given values 1 through 5, with the response corresponding to perfect adherence assigned 1. The three scores are averaged if at least 2 of the 3 items have responses. Non-adherence is defined as an average score of greater than 1. Will be assessed on the S1904 Breast Cancer Risk-Reducing Pill Usage form.
Measured: Up to 5 years
Reasons for chemoprevention discontinuation
For patients who report discontinuing a SERM or AI, reasons for discontinuing chemoprevention are reported on the S1904 Breast Cancer Risk-Reducing Pill Usage form.
Measured: Up to 5 years
Shared decision-making
Will be assessed by a validated 9-item scale with Likert-style responses to assess shared decision-making about chemoprevention. Scores range from 0 to 100. Provider and patient measures are evaluated separately and scored according to their respective validation papers. Will be assessed on the S1904 Patient Shared Decision-Making Questionnaire and on the S1904 Provider Shared Decision-Making Questionnaire.
Measured: Up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2020
- Study start23 Oct 2020
- Primary completion1 Sep 2025
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Atypical Hyperplasia of the BreastStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 412 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Katherine D Crew, Principal investigator, SWOG Cancer Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04496739
- Sponsor's protocol ID
- S1904
- Other IDs
- NCI-2019-08755, S1904, SWOG-S1904, S1904, R01CA226060, UG1CA189974
- Status last verified
- Apr 2026
- First submitted
- 29 Jul 2020
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Crew KD, Anderson GL, Arnold KB, Dzingle S, Michel A, DeLucie M, Law CW, Pruthi S, Sandoval Leon AC, Shirley R, Grosse Perdekamp MT, Colonna SV, Krisher SL, King TA, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino DA, Wisinski KB, DeYoung CA, Ross M, Floyd JD, Kaster A, VanderWalde LH, Saphner TJ, Zarwan C, Lo S, Graham C, Conlin AK, Yost Butler K, Agnese DM, Jernigan C, Hershman DL, Neuhouser ML, Zell JA, Arun B, Kukafka R. Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE. J Natl Cancer Inst. 2026 Jul 2:djag216. doi: 10.1093/jnci/djag216. Online ahead of print.
PubMed 42391096Michel AM, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S, Anderson G, Arnold K, Law C, Pruthi S, Sandoval-Leon A, Shirley R, Perdekamp MG, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino DA, Wisinski K, DeYoung CA, Ross M, Floyd J, Kaster A, VanderWalde L, Saphner TJ, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Crew KD, Kukafka R. Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904). BMC Med Inform Decis Mak. 2024 Sep 27;24(1):272. doi: 10.1186/s12911-024-02691-0.
PubMed 39334347Crew KD, Anderson GL, Arnold KB, Stieb AP, Amenta JN, Collins N, Law CW, Pruthi S, Sandoval-Leon A, Bertoni D, Grosse Perdekamp MT, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino D, Wisinski KB, DeYoung CA, Ross M, Floyd J, Kaster A, Vander Walde L, Saphner T, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Kukafka R. Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. Contemp Clin Trials. 2024 Jul;142:107564. doi: 10.1016/j.cct.2024.107564. Epub 2024 May 3.
PubMed 38704119McGuinness JE, Bhatkhande G, Amenta J, Silverman T, Mata J, Guzman A, He T, Dimond J, Jones T, Kukafka R, Crew KD. Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools. Cancer Prev Res (Phila). 2022 Jun 2;15(6):399-406. doi: 10.1158/1940-6207.CAPR-21-0593.
PubMed 35412592